Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States

被引：16

作者：

Goyal, Ravi K. ^{[1
]}

Nagar, Saurabh P. ^{[1
]}

Kabadi, Shaum M. ^{[2
]}

Kaye, James A. ^{[3
]}

Seal, Brian ^{[2
]}

Mato, Anthony R. ^{[4
]}

机构：

[1] RTI Hlth Solut, Res Triangle Pk, NC USA

[2] AstraZeneca, Gaithersburg, MD USA

[3] RTI Hlth Solut, Waltham, MA USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 04期

关键词：

Mantle cell lymphoma; MCL; economic burden; costs; treatment patterns; adverse events; 1ST-LINE TREATMENT; PLUS RITUXIMAB; OPEN-LABEL; IBRUTINIB; COSTS; MCL; MULTICENTER; EFFICACY; INDOLENT; THERAPY;

D O I：

10.1080/10428194.2018.1509320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In view of recent therapeutic advances in mantle cell lymphoma (MCL), the aim of this retrospective cohort analysis was to assess treatment patterns, adverse events (AEs), resource utilization, and health care costs in patients with MCL in a US-based commercial claims database. A total of 783 patients with MCL (median age = 65 years) were selected. Among patients receiving systemic therapy (n = 457), the most common treatment regimens were bendamustine/rituximab (BR) (41.1%), rituximab/cyclophosphamide/doxorubicin/vincristine (RCHOP) (26.7%), rituximab monotherapy (20.4%), and ibrutinib monotherapy (14.2%). Mean monthly costs during treatments with BR, RCHOP, rituximab, and ibrutinib were $12,958, $24,719, $13,153, and $21,690, respectively. Mean monthly cost during follow-up was $13,650 among patients with >= 6 AEs versus $5131 among those without AEs. The costs of MCL varied considerably by treatment regimen and care setting. The overall economic burden of managing patients with MCL can be substantially affected by costs associated with managing AEs occurring during treatment.

引用

页码：955 / 963

页数：9

共 30 条

[1] Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry [J].

Abrahamsson, Anna ;

Dahle, Nina ;

Jerkeman, Mats .

LEUKEMIA & LYMPHOMA, 2011, 52 (10) :1929-1935

[2]

[Anonymous], 2017, CLIN PRACT GUID ONC

[3]

[Anonymous], 2014, MANTL CELL LYMPH FAC

[4] Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials [J].

Brown, Jennifer R. ;

Moslehi, Javid ;

O'Brien, Susan ;

Ghia, Paolo ;

Hillmen, Peter ;

Cymbalista, Florence ;

Shanafelt, Tait D. ;

Fraser, Graeme ;

Rule, Simon ;

Kipps, Thomas J. ;

Coutre, Steven ;

Dilhuydy, Marie-Sarah ;

Cramer, Paula ;

Tedeschi, Alessandra ;

Jaeger, Ulrich ;

Dreyling, Martin ;

Byrd, John C. ;

Howes, Angela ;

Todd, Michael ;

Vermeulen, Jessica ;

James, Danelle F. ;

Clow, Fong ;

Styles, Lori ;

Valentino, Rudy ;

Wildgust, Mark ;

Mahler, Michelle ;

Burger, Jan A. .

HAEMATOLOGICA, 2017, 102 (10) :1796-1805

[5] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[6] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[7] Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study [J].

Chanan-Khan, Asher ;

Cramer, Paula ;

Demirkan, Fatih ;

Fraser, Graeme ;

Silva, Rodrigo Santucci ;

Grosicki, Sebastian ;

Pristupa, Aleksander ;

Janssens, Ann ;

Mayer, Jiri ;

Bartlett, Nancy L. ;

Dilhuydy, Marie-Sarah ;

Pylypenko, Halyna ;

Loscertales, Javier ;

Avigdor, Abraham ;

Rule, Simon ;

Villa, Diego ;

Samoilova, Olga ;

Panagiotidis, Panagiots ;

Goy, Andre ;

Mato, Anthony ;

Pavlovsky, Miguel A. ;

Karlsson, Claes ;

Mahler, Michelle ;

Salman, Mariya ;

Sun, Steven ;

Phelps, Charles ;

Balasubramanian, Sriram ;

Howes, Angela ;

Hallek, Michael ;

Assouline, S. ;

Bence-Bruckler, I. ;

Buckstein, R. ;

Fraser, G. ;

Larratt, L. ;

Minuk, L. ;

Villa, D. ;

Angevine, A. ;

Bartlett, N. ;

Bixby, D. ;

Caimi, P. ;

Chanan-Khan, A. ;

Craig, M. ;

Forero-Torres, A. ;

Ganguly, S. ;

Goy, A. ;

Heffner, L. ;

Hermann, R. ;

Lansigan, F. ;

Leis, J. ;

Letzer, J. .

LANCET ONCOLOGY, 2016, 17 (02) :200-211

[8] The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients [J].

Charlson, Mary E. ;

Charlson, Robert E. ;

Peterson, Janey C. ;

Marinopoulos, Spyridon S. ;

Briggs, William M. ;

Hollenberg, James P. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (12) :1234-1240

[9] Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients [J].

Chyou, Janice Y. ;

Hunter, Tina D. ;

Mollenkopf, Sarah A. ;

Turakhia, Mintu P. ;

Reynolds, Matthew R. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (07)

[10] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings [J].

Czuczman, Myron S. ;

Goy, A. ;

Lamonica, D. ;

Graf, D. A. ;

Munteanu, M. C. ;

van der Jagt, R. H. .

ANNALS OF HEMATOLOGY, 2015, 94 (12) :2025-2032

← 1 2 3 →